Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals

  • In Health
  • 2023-01-26 17:35:18Z
  • By Reuters

WASHINGTON (Reuters) - Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.

"Given these companies' records of anti-competitive

business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.

The agency shares the job of assessing mergers to ensure they comply with antitrust law with the Justice Department. It can sue to block planned acquisitions that it believes are illegal.

Warren said that both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon's Krystexxa, a gout medication.

She noted that the FTC had settled with Indivior and its former parent over its attempt to protect its monopoly of the opioid addiction treatment Suboxone. Indivior makes Sublocade -- a slow-release treatment for opioid addiction that is administered monthly. Suboxone is given daily and also prevents an accidental overdose.

Opiant, original owner of opioid overdose remedy Narcan, is working on getting approval for a nasal spray version of nalmefene, believed to be a more effective opioid antagonist.

"The FTC should strongly consider Indivior's history of anti-competitive and deceptive practices when evaluating how

Indivior might behave after this potential transaction is completed," wrote Warren.

Warren noted that the FTC, which has long focused on healthcare mergers, said in 2021 that it would prioritize pharmaceutical acquisitions. She also asked the agency how it factored into its merger reviews efforts by the companies to extend patent protections, using strategies that are sometimes controversial.

(Reporting by Diane Bartz; Editing by Chizu Nomiyama)


More Related News

Full transcript of "Face the Nation" on March 19, 2023
Full transcript of "Face the Nation" on March 19, 2023

On this "Face the Nation" broadcast, Sen. Elizabeth Warren, Democratic of Massachusetts, and Rep. Patrick McHenry, Republican of North Carolina, join...

Warren Says She Favors Increasing FDIC
Warren Says She Favors Increasing FDIC's Deposit Insurance Cap

(Bloomberg) -- Senator Elizabeth Warren is calling for more US deposits to be covered by federal insurance and is demanding government probes into whether...

Elizabeth Warren says Fed chair
Elizabeth Warren says Fed chair 'failed' and calls for inquiry into bank collapse

Progressive Democrat launches offensive on politicians on the left and the right who supported Trump-era deregulation of US banks

Elizabeth Warren Says Fed Chair Powell Took
Elizabeth Warren Says Fed Chair Powell Took 'Flamethrower' to Bank Regulations

Democratic Senator Elizabeth Warren blamed Federal Reserve Chair Jerome Powell on Sunday for allegedly taking a "flamethrower" to regulations in the...

Warren argues Federal Reserve interest rate hikes should stop
Warren argues Federal Reserve interest rate hikes should stop

Sen. Elizabeth Warren (D-Mass.) on Sunday argued that the Federal Reserve should stop hiking interest rates in an effort to control high inflation. "I do not...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


  • Erussymer
    (2023-03-08 23:06:08Z)

    Population attributable fractions of risk factors for hepatocellular carcinoma in the United States buy cialis and viagra online


Top News: Health